

GALNT9 Antibody (Center) Blocking Peptide

Synthetic peptide Catalog # BP17972c

Specification

GALNT9 Antibody (Center) Blocking Peptide - Product Information

Primary Accession <u>Q9HCQ5</u>

GALNT9 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 50614

Other Names

Polypeptide N-acetylgalactosaminyltransferase 9, Polypeptide GalNAc transferase 9, GalNAc-T9, pp-GaNTase 9, Protein-UDP acetylgalactosaminyltransferase 9, UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase 9, GALNT9

Format

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

GALNT9 Antibody (Center) Blocking Peptide - Protein Information

Name GALNT9

Function

Catalyzes the initial reaction in O-linked oligosaccharide biosynthesis, the transfer of an N-acetyl-D-galactosamine residue to a serine or threonine residue on the protein receptor. Does not glycosylate apomucin or SDC3.

Cellular Location

Golgi apparatus membrane; Single- pass type II membrane protein

Tissue Location

Specifically expressed in brain. Not expressed in heart, placenta, lung, liver, skeletal muscle, kidney, pancreas, spleen, thymus, prostate, testis, ovary, small intestine, colon and leukocyte. In brain, it is expressed in cerebellum, frontal lobe, temporal lobe, putamen and spinal cord, weakly expressed in cerebral cortex. Not expressed in medulla and occipital pole

GALNT9 Antibody (Center) Blocking Peptide - Protocols



Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides

GALNT9 Antibody (Center) Blocking Peptide - Images

GALNT9 Antibody (Center) Blocking Peptide - Background

This gene encodes a member of

theUDP-N-acetyl-alpha-D-galactosamine:polypeptideN-acetylgalactosaminyltransferase (GalNAc-T) family of enzymes.GalNAc-Ts initiate mucin-type O-linked glycosylation in the Golgiapparatus by catalyzing the transfer of GalNAc to serine andthreonine residues on target proteins. They are characterized by anN-terminal transmembrane domain, a stem region, a lumenal catalyticdomain containing a GT1 motif and Gal/GalNAc transferase motif, anda C-terminal ricin/lectin-like domain. GalNAc-Ts have different,but overlapping, substrate specificities and patterns of expression. This gene is expressed specifically in the brain, withhighest expression in the cerebellum. Multiple transcript variantsencoding different isoforms have been found for this gene.

GALNT9 Antibody (Center) Blocking Peptide - References

Wang, A.G., et al. Biochem. Biophys. Res. Commun. 345(3):1022-1032(2006)Zhang, Y., et al. J. Biol. Chem. 278(1):573-584(2003)Toba, S., et al. Biochim. Biophys. Acta 1493 (1-2), 264-268 (2000):